secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2026-07-02T21:25:27+00:00
Accession:  0001493152-26-031972
Event type: other_material
Sentiment:  negative
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akari Therapeutics AGM: Director James Neal not re-elected; committee appointments made
--------------------------------------------------------------------------------

- James Neal failed to receive requisite shareholder approval; his directorship ended at AGM conclusion.
- Board appointed Dr. Ray Prudo to Audit Committee and Robert Bazemore as Chair of Compensation Committee.
- All other 16 resolutions passed, including re-election of five directors and ratification of BDO as auditor.
- Shareholders approved issuance of shares under ELOC and warrants from May 20, 2026 private placement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000149315226031972/0001493152-26-031972-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000149315226031972/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-031972

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer